Evidence map›Paper›PMID 37728819›Full record

ReviewCurrent treatment options in oncology2023

Mitigating Radiotoxicity in the Central Nervous System: Role of Proton Therapy.

Sebastian F Winter, Eugene J Vaios, Helen A Shih, Clemens Grassberger, Michael W Parsons, Melissa M Gardner, Felix Ehret, David Kaul, Wolfgang Boehmerle, Matthias Endres and 1 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current treatment options in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Value of artificial intelligence in neuro-oncology.The Lancet. Digital health · 2025
    Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Sebastian F WinterDepartment of Neurology and MGH Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. sfwinter@mgh.harvard.edu.
Eugene J VaiosDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.
Helen A ShihDepartment of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Clemens GrassbergerDepartment of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Michael W ParsonsDepartment of Psychiatry, Psychology Assessment Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Melissa M GardnerDepartment of Psychiatry, Psychology Assessment Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Felix EhretBerlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Junior Clinician Scientist Program, 10117, Berlin, Germany.
David KaulDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353, Berlin, Germany.
Wolfgang BoehmerleDepartment of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117, Berlin, Germany.
Matthias EndresDepartment of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117, Berlin, Germany.
Jorg DietrichDepartment of Neurology and MGH Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Harvard University · USHumboldt-Universität zu Berlin · DEMassachusetts General Hospital · USCharité - Universitätsmedizin Berlin · DEDuke Medical Center · US

Funding

Duke Radiation Oncology and Radiology Stimulating Access to Research in ResidencyR38CA245204 · NCI · DUKE UNIVERSITY · PI FLOYD, SCOTT R · 2020 to 2023
$1.4M
NCI NIH HHS R38 CA245204
6 · The paper itself

Abstract

opinion statementCentral nervous system (CNS) radiotoxicity remains a challenge in neuro-oncology. Dose distribution advantages of protons over photons have prompted increased use of brain-directed proton therapy. While well-recognized among pediatric populations, the benefit of proton therapy among adults with CNS malignancies remains controversial. We herein discuss the role of protons in mitigating late CNS radiotoxicities in adult patients. Despite limited clinical trials, evidence suggests toxicity profile advantages of protons over conventional radiotherapy, including retention of neurocognitive function and brain volume. Modelling studies predict superior dose conformality of protons versus state-of-the-art photon techniques reduces late radiogenic vasculopathies, endocrinopathies, and malignancies. Conversely, potentially higher brain tissue necrosis rates following proton therapy highlight a need to resolve uncertainties surrounding the impact of variable biological effectiveness of protons on dose distribution. Clinical trials comparing best photon and particle-based therapy are underway to establish whether protons substantially improve long-term treatment-related outcomes in adults with CNS malignancies.

Indexed as

Central Nervous System NeoplasmsProton TherapyAdultCentral Nervous SystemChildHumansPhotonsProtonsRadiotherapy DosageProtonsAdult patientsComplicationsNeurotoxicityProtonsRadiation injuryRadiotoxicity

Identifiers

PMID37728819
PMCPMC12180537
OpenAlexW4386878660

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.